ANG-First Trial (Angiotensin II as First-Line Vasopressor Therapy in Cardiac Surgery)
Part of paid clinical trials in Towson, Maryland.
- Sponsor
- University of Maryland St. Joseph Medical Center
- Study ID
- NCT06487585
- Phase
- PHASE4
- Status
- Recruiting
Conditions
- Vasodilatory Hypotension During or After Cardiac Surgery
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Accepted
Interventions
- Angiotensin II — DRUGAngiotensin II: Starting dose of 2.5 ng/kg/min administered IV; may dose escalate up to 80 ng/kg/min in order to achieve a MAP of 65 mmHg or higher in the first 3 hours. After 3 hours, may escalate dose up to 40 ng/kg/min in order to achieve a MAP of 65 mmHg. Dose titration in increments of 10 ng/kg/min every 2 minutes.
Study Details
The purpose of this research is to evaluate the use of Angiotensin II in patients with low blood pressure post-surgery. Your information will be collected for 28 days post the procedure and initiation of the study drug to assess for safety events and complications.
Key Dates
- Start date
- May 6, 2025
- Status verified
- Dec 2025
- Primary completion
- Jan 31, 2026
- Completion
- Feb 28, 2026
Study Design
- Enrollment
- 100 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Other: Study Drug Arm - Angiotensin II armAngiotensin II
Primary Outcome Measure
Incidence of postoperative acute kidney injury, atrial fibrillation [ Time Frame: 28 days ]
Central Contacts
- Aja Janyavula410-427-5459
- Sam Rudow410-427-5459
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Maryland St. Joseph Medical Center | Towson | Maryland | 21204 | Rawn Salenger, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Towson, MD
By research site